将药物警戒中的利益相关方参与系统化:基于国际风险治理框架的实用决策指南
本研究检验国际风险治理委员会(IRGC)框架是否适用于药物警戒,并以欧洲药品管理局(EMA)六个标志性案例进行概念验证。结果显示,各案例按IRGC风险情景分类后,实际参与事件的范围/结局与框架推荐的话语特征相对应。据此提出决策指南,以帮助监管者在特定风险情景下系统选择与患者和医护人员的参与机制。
要点
- IRGC框架可用于对药物警戒参与事件进行风险情景分类。
- 六个EMA标志性案例的参与范围与IRGC推荐话语特征相对应。
- 所提决策指南旨在系统化选择患者与医护人员参与机制。
核心结论
- IRGC框架似乎适用于药物警戒,可指导选择不同风险情景下的利益相关方参与机制。
研究设计与样本
- 概念验证研究,对欧洲药品管理局(EMA)六个标志性药物警戒参与案例按IRGC风险情景类型进行分类,并比较实际参与与IRGC推荐话语。
主要发现
- 六个案例被分类为:复方激素避孕药与静脉血栓栓塞(复杂风险);HAART药物与脂肪营养不良、受污染奈非那韦产品与致癌性(不确定风险);沙利度胺与致畸性、那他珠单抗与进行性多灶性白质脑病、丙戊酸与致畸性及发育障碍(模糊风险)。
- 参与事件的范围/结局与IRGC推荐话语的特征之间显示对应关系。
关键数值与推荐
- 复杂风险案例:复方激素避孕药与静脉血栓栓塞。
- 不确定风险案例:HAART药物与脂肪营养不良;受污染奈非那韦产品与致癌性。
- 模糊风险案例:沙利度胺与致畸性;那他珠单抗与进行性多灶性白质脑病;丙戊酸与致畸性及发育障碍。
临床怎么用
- 监管者可依据IRGC风险情景分类,系统选择与患者和医护人员的参与机制,以获取真实世界输入用于风险评估、风险最小化措施评价和决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Input from patients and healthcare professionals to regulatory assessments is essential for benefit-risk management of medicines. How to best obtain input in different risk scenarios is uncertain. OBJECTIVES: The objective of this study was to investigate whether the International Risk Governance Council (IRGC) Framework is applicable to pharmacovigilance and can guide selecting engagement mechanisms for optimising stakeholder input. METHODS: For proof-of-concept, classify 'iconic' cases of pharmacovigilance engagement at the European Medicines Agency (EMA) by IRGC risk scenario types and compare the engagement that happened with the engagement discourse recommended by the IRGC Framework for different risk scenarios. If the concept is proven, derive proposals for strengthening engagement. RESULTS: Six iconic cases were classified by risk scenario type at the respective time points when deciding on engagement: venous thromboembolism with combined hormonal contraceptives (complex risk); lipodystrophy with highly active antiretroviral therapy medicines, carcinogenicity with contaminated nelfinavir products (uncertain risks); teratogenicity with thalidomide, progressive multifocal leukoencephalopathy with natalizumab, teratogenicity and developmental disorders with valproate (ambiguous risks). The comparison of the engagement events with IRGC recommendations showed correspondence between the scope/outcomes of the events and the features of the recommended discourse. CONCLUSIONS: The IRGC Framework appears applicable to pharmacovigilance. Proposals derived from the IRGC recommendations may be valuable for guiding regulators when selecting mechanisms for engagement with patients and healthcare professionals in given risk scenarios. The proposed decision guide aims at ensuring systematic and consistent engagement across regulatory assessments and providing for the most purposeful discourse, to effectively obtain real-world input for regulatory risk assessment, evaluation of risk minimisation measures and decision making.
引用
- Bahri P, Pariente A. Systematising Pharmacovigilance Engagement of Patients, Healthcare Professionals and Regulators: A Practical Decision Guide Derived from the International Risk Governance Framework for Engagement Events and Discourse. Drug Saf. 2021. PMID: 34528215. doi:10.1007/s40264-021-01111-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。